A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Inclusion Criteria:

• Have a histologically confirmed active CLE or SLE with cutaneous manifestations inthe form of subacute cutaneous lupus erythematosus or/and discoid/chronic cutaneouslupus erythematosus at least 3 months and CLASI-A at least 8 or higher.

• Participant has adequate intravenous infusion access per investigator's judgement

• Willing to comply with study procedures including skin punch biopsies procedures.

• Weight is greater than 40 kg and less than 130 kg.

Exclusion Criteria:

• Skin disorders other than CLE or SLE.

• Active, severe lupus nephritis requiring treatment with cytotoxic agents orhigh-dose steroids.

• Active severe central nervous system lupus requiring therapeutic intervention within 60 days of baseline.

• Cancer or a history of cancer within 5 years of screening except adequately resectedbasal or squamous cell carcinoma of the skin, or carcinoma in situ of uterinecervix.

• Known history of a major cardiovascular or cerebrovascular event within 24 months,pulmonary arterial hypertension, pulmonary embolism within 6 months of screening.

• Have any autoimmune or inflammatory disease that would interfere with interpretationof test results or clinical assessments.

• History of disseminated herpes zoster/simplex or recurrent herpes zoster.

• Serious infection within 60 days of baseline or an active infection treated withoral antibiotics within 14 days of baseline.

• Have evidence of active or latent infection of hepatitis B or C, known history ofhuman immunodeficient virus (HIV) infection, or infected with Mycobacterium TB (active or latent TB)

• Laboratory abnormalities that meet exclusion criteria at the Screening visit. Theabove information is not intended to contain all considerations relevant to apatient's potential participation in a clinical trial.